Tamoxifen is an oral selective estrogen receptor modulator which is used in breast cancer, and is currently the world's largest selling breast cancer treatment. It is used for the treatment of early and advanced breast cancer in pre- and post-menopausal women. It is also approved by the FDA for the reduction of the incidence of breast cancer in women at high risk of developing the disease. It has been further approved for the reduction of contralateral (in the opposite breast) breast cancer.
Tamoxifen was invented by ICI Pharmaceuticals (now AstraZeneca) and is sold under the brand names Nolvadex, Istubal, and Valodex. It is also available as a generic drug in a number of countries. Interestingly enough, in the United States, the drug was almost always referred by its generic name even before patent expiration.
4-hydroxytamoxifen
4-hydroxytamoxifen is a form of the drug tamoxifen that is made by the body after taking tamoxifen. It can also be made in the laboratory, and may help decrease breast density. A topical form of 4-hydroxytamoxifen is being studied in breast cancer screening.
Nolvadex is very comparable to Clomid, behaves in the same manner in all tissues, and is a mixed estrogen agonist/antagonist of the same type as Clomid.
It is not correct that Nolvadex reduces levels of estrogen: rather, it blocks estrogen from estrogen receptors and, in those tissues where it is an antagonist, causes the receptor to do nothing.
The fact that Nolvadex will reduce water retention may result in the user agreeing that gains are less, since weight gain is less, thus reinforcing the bias.
Nolvadex belongs to the group of sex hormones and is a so-called antiestrogen.
Nolvadex should especially be taken together with the strong an-drogenic steroids Dianabol and Anadrol 50, and the various test-osterone compounds.
Since Nolvadex is very affective in most cases it is no wonder that several athletes can take Anadrol 50 and Dianabol until the day of a competition, and in combination with a diuretic still appear totally ripped in the.
Feeds |
Contact